home
NEWS & MEDIA
News
Events
Media
NEWS
12.13.11
Tarsa Therapeutics Targets 2012 NDA Submission for Its Ostora™ Oral Calcitonin
09.18.11
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
07.12.11
Tarsa Therapeutics Advances Its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis
03.24.11
Tarsa Therapeutics Reports Positive Top-Line Results from Pivotal Phase III Oracal Trial of Its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
02.14.11
Tarsa Therapeutics Completes Phase III Trial of Its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
09.24.10
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
07.22.10
Tarsa Therapeutics Advances Phase III Oracal Trial of Its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
02.18.10
Tarsa Therapeutics Announces Addition of Senior Level Clinical and Regulatory Expertise
10.20.09
Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics
